FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

ype Response:	s)													
1. Name and Address of Reporting Person* Hollister John B				2. Issuer Name and Ticker or Trading Symbol Nemus Bioscience, Inc. [NMUS]					;	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner X_ Officer (give title below) Other (specify below) Chief Executive Officer				
(Last) (First) (Middle) 650 TOWN CENTER DRIVE, SUITE 620				3. Date of Earliest Transaction (Month/Day/Year) 12/04/2014										
				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
ity)	(State)	(Zip)			T	able	I - Non-Deriv	vative Securitie	es Acquire	d, Disposed	of, or Benef	icially Owned	<u> </u>	
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea			2A. Deemed Execution Date, if any (Month/Day/Year) 3. Tra Code (Instr.			8) (A	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or (Instr. 3 and (Instr. 3 and (Instr. 3))		ned Followi ensaction(s)	of Securities Beneficially owing Reported (s)		Ownership or orm: Direct (D) Cr Indirect (I)	. Nature f Indirect deneficial dwnership (Instr. 4)	
Report on a s	separate line for each		- Deriva	ativo	e Securities	s Acq	Persons in this for a current	orm are not rately valid OMI	equired to B control eficially Ov	respond ι number.				174 (9-02)
2. Conversion or Exercise Price of Derivative Security	ion Date Execution (Month/Day/Year) Execution (Month/Day/Year)	any	4. 5 Transaction Code S (Instr. 8) A		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		1 /			Derivative Securities Beneficially Owned Following Reported	Form of Derivative Security: Direct (D) or Indirec	Beneficial Ownershi (Instr. 4)
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	-	(Instr. 4)	(Instr. 4)	
. (1)	12/04/2014(1)		A ⁽¹⁾		480,000		<u>(2)</u>	10/31/2024	Commo Stock	n 480,000	\$ 0	480,000	D	
\$ 0.42 (1)	12/04/2014													
	nd Address of John B MESA, CA MESA, CA Ty) Report on a s 2. Conversion or Exercise Price of Derivative Security	nd Address of Reporting Person Dohn B Ist) WN CENTER DRIVE, SUI (Street) MESA, CA 92626 Ity) (State) Security Report on a separate line for each or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)	nd Address of Reporting Person* John B Security Report on a separate line for each class of securities by the foreign or Exercise Price of Derivative Security Security Conversion or Exercise Price of Derivative Security Conversion or Exercise Price of Derivative Security Conversion or Exercise Price of Derivative Security Conversion or Exercise Price of Derivative Security Conversion or Exercise Price of Derivative Security Conversion Or Exercise Price of Derivative Security Conversion Or Exercise Price of Derivative Security Conversion Or Exercise Price of Derivative Security Conversion Or Exercise Price of Derivative Security Conversion Or Exercise Price of Derivative Security Conversion Or Exercise Price of Derivative Security Conversion Or Exercise Price of Derivative Security Conversion Or Exercise Price of Derivative Security Conversion Or Exercise Price of Derivative Security Conversion Or Exercise Price of Derivative Security Conversion Or Exercise Price of Derivative Security Conversion Or Exercise Price of Derivative Security Conversion Or Exercise Price of Derivative Security Conversion Or Exercise Price of Derivative Security Conversion Or Exercise Price of Derivative Security Conversion Or Exercise Price of Derivative Security Conversion Or Exercise Price of Or Exercise Price Or Exerci	Address of Reporting Person* John B 2. Isst Nemu 3. Date 12/04/ (Street) MESA, CA 92626 ty) (State) Security 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) Table II - Derivative Security 3. Date 12/04/ 4. If Ar Table II - Derivative Security 3. A. Deemed Exect Exect any (Month/Day/Year) A Transaction Date (Month/Day/Year) Month/Day/Year) A Transaction Date (Month/Day/Year) A Transaction Date (Month/Day/Year) Code Code Code Code	Address of Reporting Person 2. Issuer Nemus B Sist) (First) (Middle) WN CENTER DRIVE, SUITE 620 (Street) 4. If Amend MESA, CA 92626 (Sty) (State) (Zip) Security 2. Transaction Date (Month/Day/Year) Report on a separate line for each class of securities beneficially of the company of t	Address of Reporting Person Nemus Bioscience (Middle) WN CENTER DRIVE, SUITE 620 (Street) MESA, CA 92626 ty) Security 2. Transaction Date (Month/Day/Year) Report on a separate line for each class of securities beneficially owned direct (Month/Day/Year) Table II - Derivative Securities (e.g., puts, calls, warried) Conversion or Exercise Price of Derivative Security 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Date of Earliest Transaction Execution Date (Month/Day/Year) 2. Transaction Date (e.g., puts, calls, warried) Execution Date, if Transaction Code (Instr. 8) (Month/Day/Year) (Month/Day/Year) Code V (A)	Address of Reporting Person* John B Set John John B Set John John B Set John John John John John John John John	And Address of Reporting Person - Tolon B Set John B	And Address of Reporting Person Dohn B Set (First) (Middle) (Street) WN CENTER DRIVE, SUITE 620 (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) MESA, CA 92626 (State) (Zip) Table I - Non-Derivative Securities Acquired (A) or Disposed of Ceg., puts, calls, warrants, options, convertible security (Month/Day/Year) Report on a separate line for each class of securities beneficially owned directly or indirectly. Table II - Derivative Securities Acquired (A) or Disposed of Conversion or Exercise Price of Derivative Security (Month/Day/Year) And Address of Reporting Person* 2. Issuer Name and Ticker or Trading Symbol Nemus Bioscience, Inc. [NMUS] 3. Date of Earliest Transaction (Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) And Source Securities Acquired (A) or Disposed of (Instr. 8) And Source Securities Acquired (A) or Disposed of (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 8) Execution Date (Reg., puts, calls, warrants, options, convertible secure (Instr. 8) Acquired (A) or Disposed of (Instr. 8) Code V (A) (D) Date Exercisable and Expiration Date (Month/Day/Year) Code V (A) (D) Date Exercisable Expiration Exercisable Expiration Exercisable Expiration	2. Issuer Name and Ticker or Trading Symbol Nemus Bioscience, Inc. [NMUS] 3. Date of Earliest Transaction (Month/Day/Year) 2/2/04/2014 4. If Amendment, Date Original Filed(Month/Day/Year) 6. X 4. If Amendment, Date Original Filed(Month/Day/Year) 6. X 6	Address of Reporting Person - South B 2. Issuer Name and Ticker or Trading Symbol Nemus Bioscience, Inc. [NMUS] 3. Date of Earliest Transaction (Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) (State) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 4. Securities Acquired (Day or indirectly. 2. Described by Month (A) or Disposed of (D) (Instr. 3, 4, and 5) 4. Securities Acquired (Day or Disposed of, or Beneficially Owned (E.g., puts, calls, warrants, options, convertible securities) 2. Date Exercisable and Expiration Date (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (Day (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (Day (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (Day (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (Day (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (Day (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (Day (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (Day (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (Day (Month/Day/Year) 4. Securities Acquired (A) or Dis	Address of Reporting Person - Volum B Code V Amount Code V Code V Code V Code V Code V Code Cod	Check all applicable Nemus Bioscience, Inc. [NMUS] X. Director 19%, Chief Executive Office 19%, Chief Executive 19%,	Address of Reporting Person Company Control Cont

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Hollister John B 650 TOWN CENTER DRIVE SUITE 620 COSTA MESA, CA 92626	X		Chief Executive Officer			

Signatures

/s/ John B. Hollister	12/05/2014
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- The Board of Directors of the Company approved the grant of Stock Options on October 31, 2014, at an exercise price of fair market value. The Company engaged an independent third (1) party to establish the fair market value on the date of grant. On December 4, 2014, the Board of Directors of the Company accepted the valuation report and set the exercise price at \$0.42
- (2) Reporting Person's right to receive Stock Options vest over a five year period, with the first 20% of the total Stock Options vesting on the one year anniversary of the grant date the remainder of the shares will vest in equal installments on a annual basis thereafter, such that the Stock Options are fully vested on October 31, 2019.
- The Board of Directors of the Company approved the grant of Stock Options on November 21, 2014, at an exercise price of fair market value. The Company engaged an independent third (3) party to establish the fair market value on the date of grant. On December 4, 2014, the Board of Directors of the Company accepted the valuation report and set the exercise price at \$0.42 per share.
- (4) Reporting Person's right to receive Stock Options vest over a five year period, with the first 20% of the total Stock Options vesting on the one year anniversary of the grant date the remainder of the shares will vest in equal installments on a annual basis thereafter, such that the Stock Options are fully vested on November 21, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.